SCO-240 is under clinical development by Scohia Pharma and currently in Phase I for Diabetes. According to GlobalData, Phase I drugs for Diabetes have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SCO-240’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SCO-240 overview

SCO-240 is under development for the treatment of diabetes, cholelithiasis, gall stone, primary sclerosing cholangitis and hepatobiliary disease. It is administered through oral route. It acts by targeting somatostatin receptor type 5 (SSTR5).

Scohia Pharma overview

Scohia Pharma is a bio-pharmaceutical company which develops and commercializes novel therapeutics for metabolic, cardiovascular and renal diseases. The company product pipeline includes SCO-272, SCO-792, SCO-094, SCO-267, SCO 240, SCO 006 and SCO 116. Its SCO-272 candidates acts as an an inhibitor for the treatment of hypertension, SCO-792 is an oral drug for the treatment of obesity, SCO-094 is an injectable peptide for the treatment of diabetes and SCO-267 is an oral agonist. Scohia Pharma services comprises pharmacological research, synthetic research and clinical development, among others. It serves in the therapeutic areas of blood glucose, blood pressure and lipids. Scohia Pharma is headquartered in Fujisawa, Kanagawa, Japan.

For a complete picture of SCO-240’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 21 December 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.